CindyAnneLeissingerMD
Oncology • New Orleans, LAProfessor, Medicine, Tulane University School of Medicine
Are you Dr. Leissinger?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 56 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1415 Tulane Ave
HC62
New Orleans, LA 70112Phone+1 504-988-6300Fax+1 504-988-6348
Summary
- Dr. Cindy Leissinger, MD is an oncologist in New Orleans, Louisiana. She is currently licensed to practice medicine in Louisiana and Texas. She is affiliated with Tulane Medical Center and University Medical Center.
Education & Training
Tulane UniversityFellowship, Hematology and Medical Oncology, 1990- Tulane UniversityResidency, Internal Medicine, 1979 - 1982
- Tulane University School of MedicineClass of 1979, MD
Certifications & Licensure
LA State Medical License 1979 - 2025
TX State Medical License 2023 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Optimal Platelet Dose Strategy for Management of Thrombocytopenia Start of enrollment: 2004 Jul 01
- Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors Start of enrollment: 2003 Jun 01
- Rituximab to Treat Severe Hemophilia A Start of enrollment: 2006 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsLack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk.Pooja Vir, Devi Gunasekera, Batsukh Dorjbal, Dennis McDaniel, Atul Agrawal
Journal of Thrombosis and Haemostasis. 2024-12-01 - 2 citationsAnother Victory for Patients with Hemophilia.Cindy Leissinger
The New England Journal of Medicine. 2023-01-26 - 2 citationsHemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life.Miguel A Escobar, Cindy Leissinger, Guy Young
Journal of the Advanced Practitioner in Oncology. 2022-05-01
Press Mentions
Efanesoctocog Alfa Reduces Bleeding, Pain in Phase 3 StudyJanuary 27th, 2023- New Hemophilia Treatment a Victory for Patients, Tulane Doctor Writes in New England Journal of MedicineJanuary 26th, 2023
- New Class of Factor VIII Replacement Therapy Prevents Bleeds in Severe Hemophilia AJanuary 25th, 2023
- Join now to see all
Grant Support
- Hemostasis Clinical Research Network ProtocolsNational Heart, Lung, And Blood Institute2002–2009
- Anti-Rh(D) For The Treatment Of Hepatitis C Associated Immune ThrombocytopeniaNational Center For Research Resources2006
- Evaluating The Response Of Hepatitis C To Pegylated Interferon In HemophiliacsNational Center For Research Resources2005
- Evaluating The Response Of Hepatitis C To Pegylated IFNNational Center For Research Resources2004
- Hemophilia AIDS Clinical Trials InitiativeNational Institute Of Allergy And Infectious Diseases1998–2000
- Retrovirus Induced Immune Platelet AbnormalitiesNational Center For Research Resources1996–1997
- Retrovirus-Induced Immune Platelet AbnormalitiesNational Heart, Lung, And Blood Institute1992–1995
- Retrovirus-Induced Immune Platelet AbnormalitiesNational Heart, Lung, And Blood Institute1991
